Prikaz rezultata 1 – 7 od 7 za pretragu 'Frederick S. Vizeacoumar (14851118)', vrijeme upita: 0,01s Detaljiziraj rezultate
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy od Amr El Zawily (14851115)

    Izdano 2025
    Daljnji autori: “…Frederick S. Vizeacoumar (14851118)…”
    Spremi u popis
    Spremljeno u:

Alati za pretragu: